LILRB4 and acute myeloid leukemia: An ILT3/LILRB4-directed CAR-T cell preclinical model was active against monocytic AML cells and was not toxic to normal progenitors derived from normal CD34+ umbilical cord blood in vitro or humanized hematopoiesis in a mouse model [70].